Phase
Startup
Apoglyx
Apoglyx is a pre-clinical stage company developing first-in-class Aquaporin-9 inhibitors with anti-inflammatory properties. Prioritized pipeline indications include solid tumors, intestinal perforation, and atopic dermatitis.
The company is based on the fundamental discovery of aquaporins by Nobel Laureate professor Peter Agre, Johns Hopkins University Medical School, and the extensive, collaborative scientific work with ApoGlyx founders Søren Nielsen, and Michael Rützler, at Århus University, Denmark and Per Kjellbom, Lund University, to establish that aquaporins are key pharmaceutical targets in life-threatening diseases.
New technologies for next-gen antibody therapeutics
Single Molecule Nanowire Biosensors for Diagnostics
Medicines for acute systemic inflammatory diseases
Cancer immunotherapies based in cell reprogramming
Introducing the fungal based industrial revolution
Automated microscopy image acquisition and analysis
Fighting iron deficiency
Implants of magnesium alloys
Developing future targeted immunotherapies in cancer
Digital service for patients
Ultrasound analysis for stroke risk assessment
Medical device that reduces pain during vein operation
Cloud-based solutions for genomics data
A reusable, user-friendly, and sustainable pregnancy test
Digital assistive device for post-surgical rehabilitation
Develops the first effective treatment for hypothyroidism
Builds gene therapy viral vectors
Early detection of pancreatic cancer
Bio-based vegan coating for fruits and vegetables
Equipment that improves the function of cultivated cells
Medtech solution for preventing pressure ulcers
Effective treatments for brain tumors
A new suturing choice for abdominal wall closure
Converting waste flows into valuable raw materials
Innovative systemic anti-inflammatory treatments
Safer medical needles for prostate biopsy
